Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19

被引:62
|
作者
Li, Qian [1 ,2 ,3 ]
Zheng, Xiao-Shuang [1 ,2 ,3 ]
Shen, Xu-Rui [1 ,2 ,3 ]
Si, Hao-Rui [1 ,2 ,3 ]
Wang, Xi [1 ,2 ,3 ]
Wang, Qi [1 ,2 ,3 ]
Li, Bei [1 ,2 ]
Zhang, Wei [1 ,2 ]
Zhu, Yan [1 ,2 ]
Jiang, Ren-Di [1 ,2 ,3 ]
Zhao, Kai [1 ,2 ,3 ]
Wang, Hui [4 ]
Shi, Zheng-Li [1 ,2 ]
Zhang, Hui-Lan [5 ]
Du, Rong-Hui [6 ]
Zhou, Peng [1 ,2 ,7 ,8 ]
机构
[1] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, CAS Key Lab Special Pathogens, 44 Xiaohongshan, Wuhan 430071, Peoples R China
[2] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, 44 Xiaohongshan, Wuhan 430071, Peoples R China
[3] Univ Chinese Acad Sci, Beijing, Peoples R China
[4] Wuhan Municipal Hlth Commiss, Wuchang Branch, Wuhan, Peoples R China
[5] Huazhong Univ Sci & Technol, NHC Key Lab Resp Dis, Ctr Biomed Res, Tongji Hosp,Tongji Med Coll, Wuhan, Peoples R China
[6] Wuhan Pulm Hosp, Wuhan, Peoples R China
[7] Wuhan Inst Virol, Joint Lab Infect Dis & Hlth, Wuhan, Peoples R China
[8] Wuhan Inst Virol, Wuhan Jinyintan Hosp, Wuhan, Peoples R China
关键词
SARS-CoV-2; COVID-19; long-term carrier; prolonged shedding; transmission risk;
D O I
10.1080/22221751.2020.1852058
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Following acute infection, individuals COVID-19 may still shed SARS-CoV-2 RNA. However, limited information is available regarding the active shedding period or whether infectious virus is also shed. Here, we monitored the clinical characteristics and virological features of 38 patients with COVID-19 (long-term carriers) who recovered from the acute disease, but still shed viral RNA for over 3 months. The median carrying history of the long-term carriers was 92 days after the first admission, and the longest carrying history was 118 days. Negative-positive viral RNA-shedding fluctuations were observed. Long-term carriers were mostly elderly people with a history of mild infection. Infectious SARS-CoV-2 was isolated from the sputum, where high level viral RNA was found. All nine full-length genomes of samples obtained in March-April 2020 matched early viral clades circulating in January-February 2020, suggesting that these patients persistently carried SARS-CoV-2 and were not re-infected. IgM and IgG antibodies and neutralizing-antibody pro?les were similar between long-term carriers and recovered patients with similar disease courses. In summary, although patients with COVID-19 generated neutralizing antibodies, they may still shed infectious SARS-CoV-2 for over 3 months. These data imply that patients should be monitored after discharge to control future outbreaks.
引用
收藏
页码:2571 / 2577
页数:7
相关论文
共 50 条
  • [31] Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)
    Biyan Nathanael Harapan
    Hyeon Joo Yoo
    Journal of Neurology, 2021, 268 : 3059 - 3071
  • [32] Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)
    Harapan, Biyan Nathanael
    Yoo, Hyeon Joo
    JOURNAL OF NEUROLOGY, 2021, 268 (09) : 3059 - 3071
  • [33] The Association Between Antibody Responses and Prolonged Viable Severe Acute Respiratory Syndrome Coronavirus 2 Shedding in Immunocompromised Patients: A Prospective Cohort Study
    Lim, So Yun
    Kim, Jun-Won
    Kim, Ji Yeun
    Kang, Sung-Woon
    Jang, Choi-Young
    Chang, Euijin
    Yang, Jeong-Sun
    Kim, Kyung-Chang
    Jang, Hee-Chang
    Kim, Da Sol
    Shin, Younmin
    Lee, Joo-Yeon
    Kim, Sung-Han
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (06): : 1722 - 1727
  • [34] Comment on "Comparison of severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine side effects by age groups"
    Wang, Qiongjiao
    Yang, Yun
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2022, 68 (12): : 1623 - 1623
  • [35] Cardiovascular complications of COVID-19 severe acute respiratory syndrome
    Henning, Robert J.
    AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2022, 12 (04): : 170 - 191
  • [36] Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody: Seroprevalence among Contacts of COVID-19 Cases
    Prakash, Om
    Solanki, Bhavin
    Sheth, Jay Kirtikumar
    Kadam, Mina
    Vyas, Sheetal
    INDIAN JOURNAL OF PUBLIC HEALTH, 2021, 65 (01) : 5 - 10
  • [37] Frequent detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA on hands and skin of patients with coronavirus disease 2019 (COVID-19)
    Redmond, Sarah N.
    Li, Daniel F.
    Haq, Muhammed F.
    Jones, Lucas D.
    Nguyen, Alexandria M.
    Tiktin, Margaret
    Cadnum, Jennifer L.
    Navas, Maria E.
    Bingham, Jessica
    Wilson, Brigid M.
    Donskey, Curtis J.
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2022, 43 (12) : 1976 - 1977
  • [38] SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 ISOLATION FROM PLEURAL FLUID WITH COVID-19 PNEUMONIA AND SUPERIMPOSED EMPYEMA
    Leys, Lorenzo
    Donaldson, Sahai
    Rougui, Lamiaa
    Poddar, Vishal
    CHEST, 2020, 158 (04) : 574A - 574A
  • [39] Challenges and complexities in evaluating severe acute respiratory syndrome coronavirus 2 molecular diagnostics during the COVID-19 pandemic
    Scott, Lesley E.
    Noble, Lara D.
    Singh-Moodley, Ashika
    Kahamba, Trish
    Hardie, Diana R.
    Preiser, Wolfgang
    Stevens, Wendy S.
    AFRICAN JOURNAL OF LABORATORY MEDICINE, 2022, 11 (01)
  • [40] Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
    Abedi, Farshad
    Rezaee, Ramin
    Karimi, Gholamreza
    PHARMACOLOGICAL RESEARCH, 2020, 156